摘要
目的:探讨巴曲酶与纤溶酶治疗急性缺血性脑卒中的有效性及经济性。方法:选取2019年1月–12月我院收治的92例急性缺血性脑卒中患者,按随机数字表法分为巴曲酶组(46例)与纤溶酶组(46例)。两组均采取常规治疗,巴曲酶组在常规治疗基础上联合巴曲酶治疗,纤溶酶组则联合纤溶酶治疗。评估两组临床效果及经济学成本,统计两组不良反应发生情况,比较两组治疗前后神经功能缺损评分(NIHSS)、日常生活能力评分(ADL)及血液流变学指标。结果:巴曲酶组总体治疗有效率、NIHSS、ADL及血液流变学指标与纤溶酶组比较差异无统计学意义(P>0.05)。两组治疗期间未发生不良反应。巴曲酶组经济学成本显著高于纤溶酶组(P<0.05)。结论:巴曲酶与纤溶酶治疗急性缺血性脑卒中疗效相似,但注射用纤溶酶经济学价值可能更高。
Objective:To explore the effectiveness and economy of batroxobin and fibrinogenase in the treatment of acute ischemic stroke.Methods:A total of 92 patients with acute ischemic stroke who were admitted to hospital from January 2019 to December 2019 were randomly divided into the batroxobin group(46 cases)treated with batroxobin combined with routine therapy and the fibrinogenase group(46 cases)treated with fibrinogenase combined with routine therapy according to random number table method.The clinical effect,economic cost,the incidence of adverse drug reactions,the National Institutes of Health stroke scale(NIHSS),the activity of daily living(ADL)scale,and the hemorheological indexes before and after treatment between the two groups were compared.Results:There were no significant differences in the total effective rate,NIHSS,ADL and hemorheological indexes between the two groups(P>0.05).No adverse drug reactions were found in both groups.The economic cost of batroxobin group was significantly higher than that of fibrinogenase group(P<0.05).Conclusion:Batroxobin injection and fibrinogenase for injection showed similar effect in the treatment of acute ischemic stroke while fibrinogenase had higher economic value.
作者
段丹丹
张雅君
DUAN Dan-dan;ZHANG Ya-jun(Department of Pharmacy,Henan Provincial Corps Hospital of Chinese People's Armed Police Force,Zhengzhou 450052,China;Department of Pharmacy,the Affiliated Hospital of Henan University of Science and Technology,Luoyang 471000,China)
出处
《中国药物应用与监测》
CAS
2022年第1期1-3,15,共4页
Chinese Journal of Drug Application and Monitoring
